依达拉奉对急性脑梗死患者NIHSS评分及hs-CRP水平的影响

Effect of edaravone on NIHSS score and hs-CRP level in patients with acute cerebral infarction

目的总结分析依达拉奉对急性脑梗死患者NIHSS评分及hs-CRP水平的影响。方法抽取本院在2016年6月～2017年10月期间接诊并治疗的80例急性脑梗死患者,通过抽签方法分为对照组(40例)和观察组(40例),所有患者实施基础支持治疗,同时对照组采用奥扎格雷钠,观察组采用奥扎格雷钠以及依达拉奉,对比两组患者治疗前后的NIHSS评分及hs-CRP水平。结果对比NIHSS评分及hs-CRP水平,两组患者治疗后较治疗前上述指标均明显降低,差异存在统计学意义(P<0.05),在治疗后的上述指标方面,观察组低于对照组,组间差异性对比存在统计学意义(P<0.05);在治疗总有效率方面,观察组高于对照组,组间差异有统计学意义(P<0.05)。结论急性脑梗死患者在常规治疗同时加入达拉奉,可更好降低NIHSS评分以及Hs-CRP水平,从而改善患者预后,值得推广应用。

Objective To summarize and analyze the effect of Edaravone on NIHSS score and hs-CRP level in patients with acute cerebral infarction. Methods 80 patients with acute cerebral infarction received and treated in our hospital from June 2016 to October 2017 were divided into control group （40 cases） and observation group （40 cases） by drawing lots. The control group was treated with ozagrel sodium, the observation group with ozagrel sodium and Edaravone. The NIHSS score and hs-CRP level before and after treatment were compared between the two groups. Results Compared with the NIHSS score and the level of hs-CRR the two groups of patients after treatment were significantly lower than before treatment, the difference was statistically significant （P〈0.05）. The above indexes after treatment were lower in the observation group than in the control group （P〈0.05）. The total effective rate of treatment in the observation group was higher than that in the control group （P〈0.05）, and the difference between the two groups was statistically significant （P〈0.05）. Conclusion In patients with acute cerebral infarction, the addition of Dalavone in routine therapy can lower the NIHSS score and Hs-CRP level, and improve the prognosis of the patients. It is worth popularizing and applying.